Actavis, Warner Chilcott In Merger Talks
Both stressed that the negotiations were in early stages and declined to comment further.
If a deal materializes, it would create a trans-Atlantic drugmaker with a combined revenues of $8.5 billion and strong positions in different segments of the market. Actavis is the third-biggest U.S. maker of...
To view the full article, register now.